Medication alternatives for behavioural disturbance
|
|
- June Dean
- 5 years ago
- Views:
Transcription
1 Neurology 13 Medication alternatives for behavioural disturbance Many patients with dementia will in the later stages develop distressing behavioural symptoms. Antipsychotics are commonly used to treat this; however, as a class have been associated with serious adverse events in this vulnerable population. In this article we provide an overview of alternative medications. Dr Sean Carrivick* Foundation Year 2, Victoria Centre, 53 Downs Way, Swindon Dr Simon Manchip Consultant Old Age Psychiatrist Victoria Centre, 53 Downs Way, Swindon sean.carrivick@doctors.org.uk Patients with dementia commonly develop symptoms such as delusions, hallucinations, depression, agitation and aggression. Tese can be distressing for both patient and carer and are collectively known as behavioural and psychological symptoms in dementia (BPSD) the point prevalence is between 60 80%. 1 Various medications have been used to reduce these symptoms including antipsychotics. A conservative estimate of use is that one quarter (180,000) of people with dementia are treated with antipsychotics on the NHS. 2 Antipsychotics are sometimes prescribed for psychosis although the levels of psychosis are much lower than the prescribing levels recorded. Antipsychotics are used in a more general approach for BPSD. Given the vulnerable population, concern was raised regarding the safety of antipsychotics for this use during drug trials, which reported a higher level of cerebrovascular adverse events (CVAEs). Over the typical 6 12 week period of these studies a suggested number needed to harm for a CVAE was 58 and for one additional death was 100. An independent analysis of 17 pooled randomised controlled trials (RCT) showed an increase in all-cause mortality by 1.7 times with atypical antipsychotic use in patients with dementia compared with placebo. 3 Te 2008 Cochrane review on the use of atypical antipsychotics for aggression and psychosis in Alzheimer s disease concluded that both risperidone and olanzapine are useful to reduce aggression and risperidone also for psychosis although there is potential for extrapyramidal symptoms but no increased risk of falls. 4 It should be considered that in the UK only risperidone (Risperdal) has a license to be used for aggression in Alzheimer s dementia for up to six weeks but all other antipsychotic use would be off licence. Only aripiprazole (Abilify) has shown a clinically significant improvement in psychosis in dementia. 3,5 Overall, antipsychotics show minimal efficacy in treating BPSD effect sizes for most atypicals are only between 0.1 to 0.2 with a number needed to treat for clinically significant improvement of 5 to 11. In 2009, the Department of Health commissioned a report on antipsychotic use in dementia which has concluded that a proportion of antipsychotic prescriptions may be unnecessary if appropriate support were available and targeted a large reduction in their use. 2 Cholinesterase inhibitors (Aricept, Exelon, Reminyl) and memantine (Ebixa) are licensed for mild-moderate and moderatesevere Alzheimer s disease, respectively. There is some evidence that both groups may delay the onset of BPSD, providing additional benefit to using these currently available treatment options. 6 General approach to management Good practice includes thorough assessment and managing March 2012 Midlife and Beyond GM
2 14 Neurology Box 1: Cornell Scale items for depression in dementia A. Mood related signs 1. Anxiety: anxious expression, ruminations, worrying 2. Sadness: sad expression, sad voice, tearfulness 3. Lack of reactivity to pleasant events 4. Irritability: easily annoyed, short tempered B. Behavioural disturbance 5. Agitation: restlessness, hand wringing, hair pulling 6. Retardation: slow movement, slow speech, slow reactions 7. Multiple physical complaints (score 0 if GI symptoms only) 8. Loss of interest: less involved in usual activities (score only if change acutely, ie less than 1 month) C. Physical signs 9. Appetite loss: eating less than usual 10. Weight loss (score 2 if greater than 5lb in one month) 11. Lack of energy: fatigues easily, unable to sustain activities (Score only if occurred acutely, ie. in less than one month) D. Cyclic functions 12. Diurnal variation of mood: symptoms worse in the morning 13. Difficulty falling asleep: later than usual for this individual 14. Multiple awakenings during sleep 15. Early morning awakening: earlier than usual for this individual E. Ideational disturbance 16. Suicide: feels life is not worth living, has suicidal wishes or makes suicide attempt 17. Poor self esteem: self blame, self depreciation, feelings of failure 18. Pessimism: anticipation of the worst 19. Mood congruent delusions: delusions of poverty, illness or loss Scoring system: A=unable to evaluate, 0=absent, 1=mild or intermittent, 2=severe Based on symptoms and signs during the week prior to interview with no score given if symptoms result from physical disability or illness. Reproduced from: Cornell Institute for Geriatric Psychiatry, Weill Medical College of Cornell University. specific treatable causes such as delirium, infection, constipation and pain. Given the above issues, consideration of risk and benefit is essential NICE recommend that antipsychotics are only considered for severe BPSD causing significant distress or an immediate risk of harm to the person with dementia or others. 7 An atypical antipsychotic (eg. risperidone) is preferred over a typical (eg. haloperidol). If the immediate safety concerns allow, a period of watchful waiting may be useful as there is a high rate of spontaneous recovery. A Norwegian nursing home study has shown remission rates of delusions, depression and aggression/agitation of about 50% at one year independently of pharmacological treatment and this is in line with other outpatient studies. 8 Psychological and behavioural approaches should be used first such as structured social interaction or aromatherapy. However, if medication is considered the patient and carers should be involved in discussions especially as the patient may lack capacity to consent themselves. In general, the lowest effective dose of medication should be used with frequent reviews aiming for reduction or cessation where possible. Medication alternatives The consideration of non antipsychotic medications is indicated in the long and short term management which may replace the need for antipsychotics. Antidepressants Persons with dementia GM Midlife and Beyond March 2012
3 commonly have symptoms of depression and at a higher rate than the control population. 9 Older people are often susceptible to drug side effects and the anticholinergic effect of tricyclic antidepressants including delirium and cognitive dysfunction have put them out of favour. With negligible effects on cholinergic transmission, the selective serotonin reuptake inhibitors (SSRIs) do not produce these side effects and with less effect on histaminergic and adrenergic neurotransmission they also produce less sedation and postural hypotension. Due to the safety and tolerability factors of SSRIs they have been more widely studied. Patients with dementia do not report a higher rate of adverse events than those without. 10 Box 1 shows the Cornell Scale which is a useful tool for diagnosing depression in dementia. Citalopram has had positive reports including showing a significant decrease in agitation and a similar improvement in psychotic symptoms compared with risperidone over 12 weeks. Psychotic side effects such as sedation, tension and apathy were significantly lower with citalopram but interestingly a comparable increase in extrapyramidal side effects was seen with both drugs. 11 Sertraline was shown to improve dementia related agitation (DRA) particularly for aggression, irritability and motor disturbance in a relatively small treatment group of 22 people and may not be widely generalisable. 12 The 2004 Cochrane review on the use of trazodone was inconclusive due to insufficient evidence and could not therefore recommend its use, 13 and their 2009 review on using antidepressants to treat depression in dementia highlights only weak evidence to support their use. 14 The 2011 Cochrane review which included nine studies (692 individuals) suggests that from these few studies sertraline and citalopram were associated with a modest reduction in symptoms of agitation and psychosis when compared to placebo (in two studies) but few other significant differences for SSRIs or trazodone in measures of tolerability when compared to placebo or haloperidol. 15 Antidepressants are however widely used especially where behavioural difficulties may be secondary to depression or anxiety. SSRIs are usually first line as they have a favourable risk benefit ratio and are equally effective as other classes. However, there is an increased risk of bleeding especially in older people with concomitant use of non-steroidal GM Midlife and Beyond March 2012
4 Neurology 17 anti-inflammatories and warfarin or aspirin. Gastroprotection with a proton pump inhibitor and considering switching to mirtazapine would therefore be advised. 16 Cholinesterase inhibitors In the 2006 Cochrane review of 10 randomised, double blind, placebo controlled trials six months of treatment with donepezil (Aricept), galantamine (Reminyl) or rivastigmine (Exelon) in Alzheimer s disease produced a small treatment effect on behaviour disturbance as well as activities of daily living and cognitive function. 17 Donepezil in Alzheimer s disease was reviewed and showed benefits in behavioural disturbance 18 however these pivotal trials were based on patients being able to give full informed consent and attend clinic appointments. Tey presented with a low baseline of BPSD and benefits were primarily in apathy not aggression which limits translation to severe cases. Tere was only one suitable trial included in the 2003 Cochrane review of cholinesterase inhibitors in Dementia with Lewy bodies although this does suggest there is weak evidence of a benefit in behavioural disturbance with rivastigmine if tolerated. 19 Box 2: Alternative medications Antidepressants Citalopram (10 20mg/day) Sertraline (25 200mg/day) Cholinesterase inhibitors Galantamine (8 24mg/day) Donepezil (5 10mg/day) Rivastigmine (3 9mg/day) Assessed in multiple RCTs Reduces agitation associated with comorbid depression SSRIs are preferred. Adverse effects include hyponatraemia Assessed in multiple RCTs Benefits in behaviour, cognition and activities of daily living Side effects include GI disturbance. Over alertness may add to BPSD NMDA-glutamate receptor antagonist Memantine (10 20mg/day) Assessed in multiple RCT s Effect size small to medium. Can stabilise agitation, cognition and function. Usually well tolerated Antiepileptics Valproic acid Carbamazepine Benzodiazepines Lorazepam (0.5 4mg/day) Clonazepam(0.5 1mg) Clonazepam for REM sleep disorder. Others Lavender oil Melatonin Concern regarding multiple adverse effects Useful in the short term for agitation with severe anxiety Some success but the literature is mixed overall Memantine Memantine is an NMDAglutamate receptor antagonist. In 2006 the Cochrane group reviewed its use in dementia and concluded that in moderate to severe Alzheimer s disease, memantine has a small beneficial effect on behaviour as well as cognition and activities of daily living, and is well tolerated. Where agitation was already present there was no evidence to suggest it had an effect but in those without agitation they were slightly less likely to develop it. 20 A pooled analysis of three studies has shown a significant treatment advantage with memantine at 12 and 24/28 weeks from baseline agitation and aggression as well as improvement in cognitive, functional and global outcomes. 21 Clinical experience has shown memantine to be particularly useful for clinically driven behaviour and problems with verbal fluency (for example in primary progressive aphasia). NICE recommend memantine as an option for managing Alzheimer s disease for people with severe illness, or moderate illness who are intolerant or March 2012 Midlife and Beyond GM
5 18 Neurology have a contraindication to acetylcholinesterase inhibitors. 22 Accessibility is variable around the UK and it is usually only a secondary care prescribed drug. Antiepileptics Individual case reports with sodium valproate have been positive and it is still widely used clinically. However in 2009, Cochrane updated their review to include more recent trials and drew the same conclusion that valproate preparations were not effective for agitation and were associated with unacceptable levels of adverse events they do not therefore recommend it for BPSD. 23 Carbamazepine has been used for intermittent aggression but is limited by its potential for drug interactions and side effects. We await the outcome of a review on carbamazepine and oxcarbazepine (Trileptal) for BPSD. 24 Benzodiazepines Benzodiazepines are often used in primary and secondary care particularly for agitation with severe anxiety but should be considered for short term management only. However, they should be used with additional caution in the elderly due to the risk of adverse events including increasing falls risk, respiratory side effects and the development of tolerance. Tose with a short halflife such as lorazepam are preferable to minimise accumulation. The suggested dose of benzodiazepines in the elderly with dementia would be a quarter of the usual adult dose, non-specialists often start benzodiazepines at too high a dose. Clonazepam (Klonopin) is the treatment of choice for persisting and problematic REM Figure 1. Factors influencing behavioural problems in dementia sleep behaviour disorder. It is effective in controlling both dreams and behaviours with good evidence for safety and a sustained benefit. 25 Table 2 summarises the pharmacological alternatives to antipsychotics. Finally, Cochrane s systematic review of Special Care Units (these are usually part of a nursing home with trained staff, a modified environment and family involvement) finds no strong evidence of a benefit although there are no RCTs. Tey comment that implementing best practice is likely to be more important than a specialist unit itself. 26 Conclusion Dementia has a profound impact on a patient s life and additional symptoms such as agitation or aggression can be very distressing for both the patient and family/ carers. It can also lead to an increased likelihood of transfer to an Elderly Mental Illness (EMI) home. Te greatest evidence as an alternative to antipsychotic use exists for cholinesterase inhibitors and SSRI antidepressants although their slower onset and minimal effect with severe symptoms still leaves a place for antipsychotics. As part of a complete biopsychosocial assessment (see figure 1) and bearing in mind potentially serious adverse events, antipsychotics could be considered sparingly for severe cases in the short term with the longer term use of cholinesterase inhibitors, an SSRI or memantine. Excellent nursing care with behavioural interventions can however delay or stop the need for their use in many cases. Other medications such as lithium, analgesics, betaadrenoreceptor antagonists, cannabinoid receptor agonists and hormonal agents require further studies to determine a useful and GM Midlife and Beyond March 2012
6 Neurology 21 effective role in the management of behavioural and psychological symptoms in dementia. Conflict of interest: Dr Manchip has sat on advisory boards and lectured for Shire, Pfizer, Eisai, Lundbeck and Novartis. References 1. Parnetti L, Amici S, Lanari A, et al. Pharmacological treatment of non-cognitive disturbances in dementia disorders. Mechanisms of Ageing and Development 2001; 122(16): Banerjee S. The use of antipsychotic medication for people with dementia: Time for action. A report for the Minister of State for Care Services. Department of Health, London, Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebocontrolled trials. Journal of American Medical Association 2005; 294(15): Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer s disease. Cochrane Database of Systematic Reviews 2006, Issue 1 5. Schneider LS, Dagerman K, Insel, PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. American Journal of Geriatric Psychiatry 2006; 14: Optimising treatment and care for behavioural and psychological symptoms of dementia. uk/site/scripts/documents_info. php?documentid= NICE/SCIE. Dementia Supporting People with Dementia and Their Carers in Health and Social Care. London: NICE/SCIE, Geir Selbæk, Øyvind Kirkevold, Knut Engedal. The Course of Psychiatric and Behavioral Symptoms and the Use of Psychotropic Medication in patients with Dementia in Norwegian Nursing Homes-a 12 month Follow up study. The American Journal of Geriatric Psychiatry 2008; 16(7): Allen H, Jolley D, Comish J, Burns A. Depression in dementia: a study of mood in a community sample and referrals to a community service. International Journal of Geriatric Psychiatry 1997; 12: Solai, LalithKumar K, Mulsant, Benoit H, Pollock, Bruce G. Selective Serotonin Reuptake Inhibitors for Late-Life Depression - A Comparative Review. Drugs & Aging 2001; 18 (5): Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 2007; 15(11): Lanctot KL, Herrmann N, van Reekum R, et al. Gender, aggression and serotonergic function are associated with response to sertraline for behavioural disturbances in Alzheimer s disease. Int J Geriatr Psychiatry 2002; 17 (6): Martinón-Torres G, Fioravanti M, Grimley Evans J. Trazodone for agitation in dementia. Cochrane Database of Systematic Reviews 2004, Issue Bains J, Birks J, Dening T. Antidepressants for treating depression in dementia. Cochrane Database of Systematic Reviews Seitz DP, Adunuri N, Gill S, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database of Systematic Reviews 2011, Issue 2 16.NICE. Depression-Treatment and management of depression in adults, including adults with a chronic physical health problem. NICE clinical guidelines CG90. London: NICE, Birks J. Cholinesterase inhibitors for Alzheimer s disease. Cochrane Database of Systematic Reviews 2006, Issue Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer s disease. Cochrane Database of Systematic Reviews 2006, Issue Wild R, Pettit TACL, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database of Systematic Reviews 2003, Issue McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2006, Issue Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer s disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008; 69(3): NICE. Dementia-Supporting people with dementia and their carers in health and social care. NICE clinical guidelines CG42. London: NICE, November 2006 revised March Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database of Systematic Reviews 2009, Issue Tampi R, Aziz R, Kantrowitz J, et al. Carbamazepine and oxcarbazepine for the treatment of behavioural and psychological symptoms of dementia (BPSD) (Protocol). Cochrane Database of Systematic Reviews 2009, Issue Carlos H. Schenck MD, Mark W. Mahowald MD. REM Sleep Behavior Disorder: Clinical, Developmental, and Neuroscience Perspectives 16 Years After its Formal Identification in SLEEP. Sleep 2002; 25(02): Lai CKY, Yeung JHM, Mok V, Chi I. Special care units for dementia individuals with behavioural problems. Cochrane Database of Systematic Reviews 2009, Issue 4 March 2012 Midlife and Beyond GM
Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital
Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital with thanks to Jonathan Cavan for his input Aims Define BPSD and common symptoms
More informationPsychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD
Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationCognitive enhancers PINCH ME. Anticholinergic burden BPSD. Agitation, Aggression and antipsychotics
Cognitive enhancers PINCH ME Anticholinergic burden BPSD Agitation, Aggression and antipsychotics 2 types Cholinesterase inhibitors licensed for mild to moderate AD Donepezil Galantamine Rivastigmine also
More informationUSING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE?
USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE? Mugdha Thakur, MD Associate Professor of Psychiatry and Behavioral Sciences Duke University
More informationPsychotropic Strategies Handout Package
Psychotropic Strategies Handout Package Psychotropic Strategies Learning Objectives Utilize all clinical information available Assess the patient s overall condition this is essential Basic Principles
More informationAntipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationBEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA
BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA Unmet needs What might be your behavioural response to this experience? Content Definition What are BPSD? Prevalence How common are they? Aetiological
More informationMedications for treating people with dementia: summary of evidence on cost-effectiveness
Medications for treating people with dementia: summary of evidence on cost-effectiveness Martin Knapp, A-La Park and Alistair Burns PSSRU, London School of Economics and Political Science v4 23 July 2017
More informationDrugs used to relieve behavioural and psychological symptoms in dementia
alzheimers.org.uk Drugs used to relieve behavioural and psychological symptoms in dementia People with dementia may develop behavioural and psychological symptoms including restlessness, aggression, delusions,
More informationA Basic Approach to Mood and Anxiety Disorders in the Elderly
A Basic Approach to Mood and Anxiety Disorders in the Elderly November 1 2013 Sarah Colman MD FRCPC Clinical Fellow, Geriatric Psychiatry Mount Sinai Hospital, University of Toronto Disclosure No conflict
More informationPsychotropic Medication Use in Dementia
Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,
More informationManagement of Agitation in Dementia. Kimberly Triplett Ferguson, MS4
Management of Agitation in Dementia Kimberly Triplett Ferguson, MS4 Objectives 1. Review recommended evaluation of agitated patients with dementia. 2. Discuss evidence concerning nonpharmacologic management.
More informationANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good?
ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good? STEPHANIE M. OZALAS, PHARMD, BCPS, BCGP VA MARYLAND HEALTH CARE SYSTEM BALTIMORE, MD DISCLOSURES Off-label use of medications will be
More informationWHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together. Presented by
WHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together Presented by Our agenda for today Understanding behavioral symptoms in people living with dementia Briefly review key strategies
More informationDisclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA
Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer
More informationOptimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches
Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Andrea Iaboni, MD, DPhil, FRCPC Toronto Rehab Institute, UHN Learning objectives Recognize
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA 111) Appraisal
More informationGuidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care
Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia
More informationAntipsychotics for Dementia Under Control or Over-Prescribed?
Antipsychotics for Dementia Under Control or Over-Prescribed? Nathaniel Hedrick, PharmD ProCare HospiceCare, Manager of Clinical Services Learning Objectives Summarize the disease progression and most
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationNeuroPharmac Journal ISSN: Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M.
ISSNISSN ISSN: 2456-3927 NeuroPharmac Journal Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M. Alshahrani www. neuropharmac.com Jan-April 2018, Volume 3, Issue
More informationBehavioral Issues in Dementia. March 27, 2014 Dylan Wint, M.D.
Behavioral Issues in Dementia March 27, 2014 Dylan Wint, M.D. OVERVIEW Key points Depression Definitions and detection Treatment Psychosis Definitions and detection Treatment Agitation SOME KEY POINTS
More informationDonepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)
Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a
More information11/11/2016. Disclosures. Natural history of BPSD. Objectives. Assessment of BPSD. Behavioral Management of Persons with Alzheimer s Disease
Disclosures Behavioral Management of Persons with Alzheimer s Disease Wisconsin Association of Medical Directors November 17, 2016 Art Walaszek, M.D. Professor of Psychiatry UW School of Medicine & Public
More informationPharmacological Treatment of Aggression in the Elderly
Pharmacological Treatment of Aggression in the Elderly Howard Fenn, MD Adjunct Clinical Associate Professor Department of Psychiatry and Behavioral Sciences Stanford University Self-Assessment Question
More informationProfessor Tony Holland, Department of Psychiatry, University of Cambridge
INFORMATION SHEET The Use of Medication for Challenging Behaviour Professor Tony Holland, Department of Psychiatry, University of Cambridge Introduction Challenging behaviours displayed by people with
More informationPrescribing for people with dementia. Carol Paton Chief Pharmacist April 2009
Prescribing for people with dementia Carol Paton Chief Pharmacist April 2009 What are the issues? 1. Minimising cognitive side effects from prescribed medicines 2. Prescribing memory enhancing drugs 3.
More informationTreatment of behavioral and psychological symptoms of dementia: a systematic review
Psychiatr. Pol. 2016; 50(4): 679 715 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: http://dx.doi.org/10.12740/pp/64477 Treatment of behavioral and psychological symptoms
More informationAppendix L: Research recommendations
1 L.1 Dementia diagnosis (amyloid PET imaging) recommendation 1 Index Test Reference Test(s) Does amyloid PET imaging provide additional diagnostic value, and is it cost effective, for the diagnosis of
More informationBEHAVIORAL PROBLEMS IN DEMENTIA
BEHAVIORAL PROBLEMS IN DEMENTIA CLINICAL FEATURES Particularly as dementia progresses, psychiatric symptoms may develop that resemble discrete mental disorders such as depression or mania The course and
More informationMEDICATIONS IN MANAGING DIFFICULT BEHAVIORS
MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS A REALITY CHECK reality check Noun informal an occasion on which one is reminded of the state of things in the real world. ROBERT LACOSTE, MD MEDICAL DIRECTOR,
More informationDRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future
DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY
More informationDEMENTIA AND MEDICATION
DEMENTIA AND MEDICATION Dr. Siobhan Ni Bhriain, MRCP, MRCPsych. Clinical Director, Tallaght and SJH MHS, Consultant Old Age Psychiatrist, Chair, DSIDC Steering Committee. SUMMARY OF TODAY S TALK Dementia-definition,
More informationThe place for treatments of associated neuropsychiatric and other symptoms
The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public
More informationDementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018
Dementia NICE Guidelines Update Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018 How NICE guidelines are reviewed Multidisciplinary guideline committee established Review
More informationAppendix N: Research recommendations
Appendix N: recommendations N.1 First-line treatment of motor symptoms recommendation 1 Interventions What is the effectiveness of initial levodopa monotherapy versus initial levodopa-dopamine agonist
More informationCurrent Treatments for Dementia and Future Prospects. James Warner St Charles Hospital, London
Current Treatments for Dementia and Future Prospects James Warner St Charles Hospital, London Dementia Cognitive Non-cognitive (BPSD) Memory orientation language other cognitive abilities praxis planning
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationPharmacotherapy of Dementia Behaviors
This Clinical Resource gives subscribers additional insight related to the Recommendations published in June 2017 ~ Resource #330601 Pharmacotherapy of Dementia Behaviors (Also see our chart specific to
More informationMedications and Non-Pharma Approaches to Treatment. David J. Irwin, MD Penn Frontotemporal Degeneration Center
Medications and Non-Pharma Approaches to Treatment David J. Irwin, MD Penn Frontotemporal Degeneration Center Outline Non-Pharmacological Treatment Strategies Behavior Language Motor Supportive Care Check-points
More informationHow I Treat Aggression in Outpatients With Dementia. C. Omelan MD, FRCP(C)
How I Treat Aggression in Outpatients With Dementia C. Omelan MD, FRCP(C) Conflict of Interest I have no potential conflicts of interest to declare Overview Outline the prevalence of aggression Review
More informationPregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)
Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationDepression in Late Life
Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression
More informationAppendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)
Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Introduction / Background Treatment comes after diagnosis Diagnosis is based on
More informationFrom MCI to Dementia DR YU- MIN LIN GERIATRICIAN AUG 2018
From MCI to Dementia DR YU- MIN LIN GERIATRICIAN AUG 2018 Overview What is dementia? Common causes Normal cognitive decline Abnormal decline and mild cognitive impairment How do we manage dementia Can
More informationProfessor Tony Holland, Department of Psychiatry, University of Cambridge
INFORMATION SHEET The Use of Medication in the Treatment of Challenging Behaviour Professor Tony Holland, Department of Psychiatry, University of Cambridge Introduction The use of medication is but one
More informationUp to 90% of people with dementia experience
Focus on CME at the University of Calgary Getting Aggressive with Dementia Adrienne Cohen, MD, BSc, FRCPC Presented at Behaviour Problems in the Elderly, video-audio conference, 2003 Up to 90% of people
More informationAlzheimer s disease. The facts in brief
Alzheimer s disease Dementia is an umbrella term used to describe various conditions which damage brain cells and lead to a loss of brain function over time. Dementia causes a progressive decline in a
More informationPsychosis and Agitation in Dementia
Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University
More informationAntipsychotic Medication in Dementia; The good, the bad and the ugly! Anthony Bainbridge Deputy Director of Nursing Sheffield Health and Social Care
Antipsychotic Medication in Dementia; The good, the bad and the ugly! Anthony Bainbridge Deputy Director of Nursing Sheffield Health and Social Care Different types of antipsychotic medication Antipsychotic
More informationShriti Patel, MD Associate Program Director of Psychiatry Residency Eastern Virginia Medical School Department of Psychiatry and Behavioral Sciences
Shriti Patel, MD Associate Program Director of Psychiatry Residency Eastern Virginia Medical School Department of Psychiatry and Behavioral Sciences Disclosures Board Certified in Adult and Geriatric Psychiatry
More informationMedication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford
Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant
More informationOlder People Mental Health - new directorate/new plans. Dr Adrian Treloar Clinical director
Older People Mental Health - new directorate/new plans Dr Adrian Treloar Clinical director Dementia 700,000 people in the UK currently have dementia; this number is set to double by 2038 1/3 of people
More informationInterface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE
Cholinesterase inhibitors and Memantine are now classified as green (following specialist initiation) drugs by the Greater Manchester Medicines Management Group. Who will diagnose and decide who is suitable
More informationMulti-morbidity in Dementia: A 21st Century Challenge. Sube Banerjee. Professor of Dementia Brighton and Sussex Medical School
Multi-morbidity in Dementia: A 21st Century Challenge Sube Banerjee Professor of Dementia Brighton and Sussex Medical School Most people of any age with any long term condition have multiple conditions
More informationThe treatment of bipolar disorder in adults, children and adolescents
DRAFT FOR CONSULTATION The treatment of bipolar disorder in adults, children and adolescents The paragraphs in the draft are numbered for the purposes of consultation. The final version will not contain
More informationBehavioral and Psychological Symptoms of dementia (BPSD)
Behavioral and Psychological Symptoms of dementia (BPSD) Chris Collins - Old Age Psychiatrist, Christchurch chris.collins@cdhb.health.nz Approaching BPSD: the right mindset Assessment Non-drug management
More information-Guidelines for the discontinuation of oral antipsychotics in patients with BPSD within the primary care setting Summary- Quetiapine
-Guidelines for the discontinuation of oral antipsychotics in patients with BPSD within the primary care setting Summary- Quetiapine An independent report Time for action 1 by Professor Sube Banerjee looked
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationMANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA
MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA Dr. Dallas Seitz MD PhD FRCPC Associate Professor and Division Chair, Division of Geriatric Psychiatry Department of Psychiatry, Queen s University President,
More informationLewy Body Disease. Dementia Education for the First Responder July 27, 2017
Lewy Body Disease Dementia Education for the First Responder July 27, 2017 Dylan Wint, M.D. NV Energy Chair for Brain Health Education Cleveland Clinic Lou Ruvo Center for Brain Health OUTLINE Lewy body
More informationMedications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More informationDiscontinuing Dementia Medications Case April Patient Case
Discontinuing Dementia Medications Case April 2017 Patient Case MJ is an 86 year-old female with a primary diagnosis of Alzheimer s disease and history of anemia, cystitis, depression, Type II DM, HTN,
More informationAricept, Exelon and Reminyl the new drugs for Alzheimer s disease
PBO 930022142 NPO 049-191 Aricept, Exelon and Reminyl the new drugs for Alzheimer s disease Aricept, Exelon and Reminyl are not cures for Alzheimer s disease. However, they can temporarily slow down the
More informationBackground. Population/Intervention(s)/Comparison/Outcome(s) (PICO) Role of antidepressants in people with dementia and associated depression
updated 2012 Role of antidepressants in people with dementia and associated depression Q4: For people with dementia with associated depression, do antidepressants when compared to placebo/comparator produce
More informationDrugs for behavioural and psychological symptoms in dementia
Drugs for behavioural and psychological symptoms in dementia Factsheet 408LP January 2017 People with dementia often develop changes as their condition progresses. These include changes in their behaviour
More informationUnderstanding Dementia
Dementia Handbook for Carers Essex Understanding Dementia What is dementia? 1 Summary of dementia symptoms 4 Medication and treatment 5 1 Dementia is the name for several conditions that lead to the progressive
More informationasenapine 5mg, 10mg sublingual tablet (Sycrest ) SMC No. (762/12) Lundbeck Ltd
asenapine 5mg, 10mg sublingual tablet (Sycrest ) SMC No. (762/12) Lundbeck Ltd 10 February 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS
More informationDelirium. Quick reference guide. Issue date: July Diagnosis, prevention and management
Issue date: July 2010 Delirium Diagnosis, prevention and management Developed by the National Clinical Guideline Centre for Acute and Chronic Conditions About this booklet This is a quick reference guide
More informationPsychotropic Drug Therapy in Adults with Learning Disability. Steve Wilkinson
Psychotropic Drug Therapy in Adults with Learning Disability Steve Wilkinson Outline and Aims of the Session Drug use in learning disability Two distinct areas of drug therapy I. Treatment of common psychiatric
More informationThe burden of psychotropic drug prescribing in people with dementia: a population database study
Age and Ageing 2010; 39: 637 642 doi: 10.1093/ageing/afq090 Published electronically 12 July 2010 The Author 2010. Published by Oxford University Press on behalf of the British Geriatrics Society. All
More informationThe prevalence of dementia increases from. Pharmacological management of behavioural disturbance in patients with dementia. Dementia.
Dementia Pharmacological management of behavioural disturbance in patients with dementia Management of behavioural disturbance in the setting of dementia can be challenging. There are many potential causes
More informationPsychotropic Medication Use in Canadian Long-Term Care Patients Referred for Psychogeriatric Consultation
Original Research Psychotropic Medication Use in Canadian Long-Term Care Patients Referred for Psychogeriatric Consultation Corinne E. Fischer, MD 1,2,3, Carole Cohen, MD 3,4, Lauren Forrest, BSc 3, Tom
More informationRational Medication Use in Dementia
Rational Medication Use in Dementia Stephen Thielke sthielke@u.washington.edu (206) 764 2815 I have no conflicts of interest to report. I am an employee of the federal government. The opinions in this
More informationSession outline. Introduction to depression Assessment of depression Management of depression Follow-up Review
Depression 1 Session outline Introduction to depression Assessment of depression Management of depression Follow-up Review 2 Activity 1: Person s story followed by group discussion Present the first person
More informationPharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018
Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018 Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology UNTHSC Center for Geriatrics 855 Montgomery Street, PCC 4, Ft.
More informationAssessment and management of behavioral and psychological symptoms of dementia
Assessment and management of behavioral and psychological symptoms of dementia Helen C Kales, 1 2 3 Laura N Gitlin, 4 5 6 Constantine G Lyketsos 7 1 Section of Geriatric Psychiatry, Department of Psychiatry,
More informationDementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE
Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE Objectives At the conclusion of the session, participants will be
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationManagement of the Acutely Agitated Long Term Care Patient
Management of the Acutely Agitated Long Term Care Patient 80 60 Graying of the Population US Population Over Age 65 Millions of Persons 40 20 0 1900 1920 1940 1960 1980 1990 2010 2030 Year Defining Dementia
More informationGERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT RUTH KOHEN ASSOCIATE PROFESSOR UW DEPARTMENT OF PSYCHIATRY 5-4-2017
More informationRecognition and Management of Behavioral Disturbances in Dementia
Recognition and Management of Behavioral Disturbances in Dementia Danielle Hansen, DO, MS (Med Ed), MHSA INTRODUCTION 80% 90% of patients with dementia develop at least one behavioral disturbances or psychotic
More informationManagement of Behavioral Problems in Dementia
Management of Behavioral Problems in Dementia Ghulam M. Surti, MD Clinical Assistant Professor Department of Psychiatry and Human Behavior Warren Alpert Medical School of Brown University Definition of
More informationTechnology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217 NICE 2017. All rights reserved.
More informationCommunity Pharmacy Dementia Audit
Community Pharmacy Dementia Audit Introduction To comply with the NHS contractual requirements associated with the Clinical Governance Essential Service, pharmacy contractors must perform an annual practice
More informationCambridge University Press Effective Treatments in Psychiatry Peter Tyrer and Kenneth R. Silk Excerpt More information
Organic disorders 1 Delirium Based on Delirium by Laura Gage and David K. Conn in Effective Treatments in Psychiatry, Cambridge University Press, 2008 Introduction Delirium needs treatment for both its
More informationPRESCRIBING GUIDELINES
The Maudsley The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust PRESCRIBING GUIDELINES 10th Edition David Taylor Carol Paton Shitij Kapur informa healthcare Contents Authors
More informationPsychotropic Medication. Including Role of Gradual Dose Reductions
Psychotropic Medication Including Role of Gradual Dose Reductions What are they? The phrase psychotropic drugs is a technical term for psychiatric medicines that alter chemical levels in the brain which
More informationDIAGNOSTIC CRITERIA (ICD 10)
DEPRESSION Depression is a major public health problem around the world Affects 1:5 older people living in the community Affects 2:5 older people living in care homes Various treatment options available,
More informationMental illness A Broad Overview. Dr H Pathmanandam March 2017
Mental illness A Broad Overview Dr H Pathmanandam March 2017 Introduction Mental disorders are common in primary and secondary care Many are not recognised and not treated Some receive unnecessary or inappropriate
More informationBIOLOGICAL TREATMENT IN PSYCHIATRY. PTE ÁOK Dept.of Psychiatry Pécs
BIOLOGICAL TREATMENT IN PSYCHIATRY PTE ÁOK Dept.of Psychiatry Pécs 1 SGA effects pharmacokinetic effect chemical strucrure Receptor block D2 5-HT2 α1 H-1 M Selectíve DA (D2D3) antagonists Benzamids Amisulpiride
More informationDebra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017
Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic
More informationDepression in adults: treatment and management
1 2 3 4 Depression in adults: treatment and management 5 6 7 8 Appendix V3: recommendations that have been deleted of changed from 2009 guideline Depression in adults: Appendix V3 1 of 22 1 Recommendations
More informationPiecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder
Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder Hannah Sauer, PharmD PGY1 Pediatric Pharmacy Resident Mayo Clinic 2015 MFMER slide-1 Objectives
More informationIf you have dementia, you may have some or all of the following symptoms.
About Dementia Dementia may be caused by a number of illnesses that affect the brain. Dementia typically leads to memory loss, inability to do everyday things, difficulty in communication, confusion, frustration,
More informationThis information explains the advice about supporting people with dementia and their carers that is set out in NICE SCIE clinical guideline 42.
Supporting people with dementia and their carers Information for the public Published: 1 November 2006 nice.org.uk About this information NICEclinicalguidelinesadvisetheNHSoncaringforpeoplewithspe cificconditionsordiseasesandthetreatmentstheyshouldreceive.
More informationSiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]
SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm
More informationLiterature Scan: Alzheimer s Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information